Clinical, Radiological and Microbiological Outcomes of Implants With Two Different Connection Configurations, a Split-mouth RCT.

Sponsor
University of Valencia (Other)
Overall Status
Unknown status
CT.gov ID
NCT03528330
Collaborator
(none)
20
1
2
22.7
0.9

Study Details

Study Description

Brief Summary

This study designed as a randomized controlled split-mouth trial will be conducted at the Dental Clinic of the University of Valencia. The aim will be to assess differences in clinical, radiological and microbiological outcomes between implants with 2 different connections: internal hexagon and conical connection. Following the premises, to minimize the bias related to prosthetic phase and maximize the effect of connections on MBL changes, a 1abutment-1time protocol will be used.

The study hypothesis is that there will be no statistically significant differences between both implant connections.

Condition or Disease Intervention/Treatment Phase
  • Device: Rehabilitation with dental implant with internal hexagon connection
  • Device: Rehabilitation with dental implant with conical connection
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Clinical, Radiological and Microbiological Outcomes of Implants With Two Different Connection Configurations, a Split-mouth RCT.
Actual Study Start Date :
Jan 8, 2018
Anticipated Primary Completion Date :
Jul 1, 2019
Anticipated Study Completion Date :
Dec 1, 2019

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Internal hexagon connection

Small flaps will be elevated to reduce any kind of injury on the periosteum and maintain the blood supply during the healing period. Patients will receive 2 implants. One implant (assigned randomly) will have internal hexagon connection. The Internal Hex (IH) implant has a 2.5mm internal hexagon and a 90° cone. The platform diameter is Ø3.5mm.

Device: Rehabilitation with dental implant with internal hexagon connection
All patients will receive an implant with internal hexagon connection. All implants will be10 mm in length and 3.75 mm in diameter. Implants will be inserted slightly subcrestal. Bone levels will be measured using a calibrated probe. Torque insertion will be assed using W&H machine Once inserted, implants will be connected to smart pegs to test primary stability. A periapical x-ray will be done after the operation. Thereafter, a specific coping for digital impression will be connected to the implant and a digital impression will be taken. Aim of this procedure will be to produce a screw retained definitive zirconia prosthesis to be adapted at the time of second surgery

Experimental: Conical connection

Small flaps will be elevated to reduce any kind of injury on the periosteum and maintain the blood supply during the healing period. Patients will receive 2 implants. One implant (assigned randomly) will have internal hexagon connection. The Conical Standard (CS) implant has a 2.5mm internal hexagon and 22° cone. The platform diameter is Ø3.1mm.

Device: Rehabilitation with dental implant with conical connection
All patients will receive an implant with conical connection. All implants will be10 mm in length and 3.75 mm in diameter. Implants will be inserted slightly subcrestal. Bone levels will be measured using a calibrated probe. Torque insertion will be assed using W&H machine Once inserted, implants will be connected to smart pegs to test primary stability. A periapical x-ray will be done after the operation. Thereafter, a specific coping for digital impression will be connected to the implant and a digital impression will be taken. Aim of this procedure will be to produce a screw retained definitive zirconia prosthesis to be adapted at the time of second surgery

Outcome Measures

Primary Outcome Measures

  1. Peri-implant bone level changes [a. implant placement (baseline), b. abutment connection (8-12 weeks), c. after 1 year of function (14-15 months), d. after 3 years of function (38-39 months).]

    calculated using intraoral digital periapical radiographs

Secondary Outcome Measures

  1. Implant failure [3 years]

    Requiring removal

  2. Prosthetic complications [3 years]

    Screw loosening or fracture, fracture of the prosthesis or of the ceramic

  3. Resonance frequency analysis values [a. implant placement (baseline) b. abutment connection (8-12 weeks)]

    Measured using Ostell Mentor

  4. Probing pocket depth [a. implant placement (baseline), b. abutment connection (8-12 weeks), c. after 1 year of function (14-15 months), d. after 3 years of function (38-39 months).]

    Measurement of peri-implant pocket depth with a periodontal probe

  5. Microbial loads [12 months after loading]

    Quantities of different microbial species assessed using 16s metagenomics

  6. Plaque [a. implant placement (baseline), b. abutment connection (8-12 weeks), c. after 1 year of function (14-15 months), d. after 3 years of function (38-39 months).]

    Presence or absence of plaque

  7. Bleeding on probing [a. implant placement (baseline), b. abutment connection (8-12 weeks), c. after 1 year of function (14-15 months), d. after 3 years of function (38-39 months).]

    Presence or absence of bleeding after probing pocket depth

Eligibility Criteria

Criteria

Ages Eligible for Study:
25 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • able to sign an informed consent form

  • aged 25 years or more

  • Any patient requiring two implant-supported crowns in the lower or upper jaw

  • Kennedy class I, II, and III;

  • teeth extracted at least 6 months before implant placement;

  • sufficient bone volumes to accommodate dental implants without augmentation procedure

Exclusion Criteria:
  • General medical and/or psychiatric contraindications to implant surgery,

  • Pregnancy or nursing,

  • Heavy smoking (more than 10 cigarettes/day),

  • Treatment with anticoagulant drugs (International Normalized Ratio under 1.8), bisphosphonates, steroid therapy or anticonvulsants drugs.

  • No regenerated bone

  • Untreated Periodontal disease and inability of the patient to maintain reasonable oral hygiene according to study requirements.

  • Patients with history of alcohol, narcotics or drug abuse. (Alcoholism: more than two bottles of beer per day)

  • Patients receiving radiotherapy, chemotherapy or any other immunosuppressive treatment, or who have been administered radiotherapy in the last 5 years. (Patients through at any time received radiotherapy to the head and neck region should be excluded anyway.)

  • Metabolic bone disorders

  • Uncontrolled bleeding disorders such as: hemophilia, thrombocytopenia, granulocytopenia.

  • Degenerative diseases.

  • Osteoradionecrosis.

  • Renal failure.

  • Organ transplant recipients.

  • HIV positive.

  • Malignant diseases.

  • Diseases that compromise the immune system.

  • Unbalanced diabetes mellitus. (HbA1c above 6.5), Uncontrolled endocrine diseases

  • Psychotic diseases.

  • Hypersensitivity to one of the components of the implant in general and titanium in particular.

  • Women who are pregnant or lactating.

  • Lack of patient cooperation.

  • Parafunctional habits, such as Bruxism or Temporomandibular joint disease.

  • Various pathologies of the oral mucosa for example: Benign mucous pemphigoid, desquamative ginigivitis, erosive lichen planus, malignancy of oral cavity, bolus erosive diseases of the oral mucosa.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Clínica Odontológica de la Universitat de Valencia, Fundación Lluis Alcanyis Valencia Spain 46010

Sponsors and Collaborators

  • University of Valencia

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
David Peñarrocha Oltra, Assistanat Postdoctoral Lecturer (Profesor Ayudante Doctor), University of Valencia
ClinicalTrials.gov Identifier:
NCT03528330
Other Study ID Numbers:
  • H1506438439563
First Posted:
May 17, 2018
Last Update Posted:
Nov 14, 2018
Last Verified:
Nov 1, 2018
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 14, 2018